BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Glass DS, Grossfeld D, Renna HA, Agarwala P, Spiegler P, Kasselman LJ, Glass AD, DeLeon J, Reiss AB. Idiopathic pulmonary fibrosis: Molecular mechanisms and potential treatment approaches. Respir Investig 2020;58:320-35. [PMID: 32487481 DOI: 10.1016/j.resinv.2020.04.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Ma H, Wu X, Li Y, Xia Y. Research Progress in the Molecular Mechanisms, Therapeutic Targets, and Drug Development of Idiopathic Pulmonary Fibrosis. Front Pharmacol 2022;13:963054. [DOI: 10.3389/fphar.2022.963054] [Reference Citation Analysis]
2 Yin D, Qiu J, Hu S, Cheng L, Li H, Cheng X, Wang S, Lu J. CAV1 is a prognostic predictor for patients with idiopathic pulmonary fibrosis and lung cancer. J Biosci 2022;47. [DOI: 10.1007/s12038-021-00245-4] [Reference Citation Analysis]
3 Skurikhin E, Madonov P, Pershina O, Ermakova N, Pakhomova A, Widera D, Pan E, Zhukova M, Sandrikina L, Artamonov A, Dygai A. Micellar Hyaluronidase and Spiperone as a Potential Treatment for Pulmonary Fibrosis. Int J Mol Sci 2021;22:5599. [PMID: 34070506 DOI: 10.3390/ijms22115599] [Reference Citation Analysis]
4 Shi L, Han Q, Hong Y, Li W, Gong G, Cui J, Mao M, Liang X, Hu B, Li X, Luo Q, Zhang Y. Inhibition of miR-199a-5p rejuvenates aged mesenchymal stem cells derived from patients with idiopathic pulmonary fibrosis and improves their therapeutic efficacy in experimental pulmonary fibrosis. Stem Cell Res Ther 2021;12:147. [PMID: 33632305 DOI: 10.1186/s13287-021-02215-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 He H, Chen J, Zhao J, Zhang P, Qiao Y, Wan H, Wang J, Mei M, Bao S, Li Q. PRMT7 targets of Foxm1 controls alveolar myofibroblast proliferation and differentiation during alveologenesis. Cell Death Dis 2021;12:841. [PMID: 34497269 DOI: 10.1038/s41419-021-04129-1] [Reference Citation Analysis]
6 González-garcía K, López-martínez A, Velázquez-enríquez JM, Zertuche-martínez C, Carrasco-torres G, Sánchez-navarro LM, Villa-treviño S, Baltiérrez-hoyos R, Vásquez-garzón VR. 3′5-Dimaleamylbenzoic Acid Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice. IJMS 2022;23:7943. [DOI: 10.3390/ijms23147943] [Reference Citation Analysis]
7 SenGupta S, Parent CA, Bear JE. The principles of directed cell migration. Nat Rev Mol Cell Biol 2021;22:529-47. [PMID: 33990789 DOI: 10.1038/s41580-021-00366-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
8 Durairaj P, Venkatesan S, Narayanan V, Babu M. Curcumin inhibition of bleomycin-induced changes in lung collagen synthesis, deposition and assembly. Mol Biol Rep 2021;48:7775-85. [PMID: 34643929 DOI: 10.1007/s11033-021-06790-3] [Reference Citation Analysis]
9 Yu B, Jin XQ, Yu WY, Dong YY, Ying HZ, Yu CH. 1β-Hydroxyalantolactone from Inulae Flos alleviated the progression of pulmonary fibrosis via inhibiting JNK/FOXO1/NF-κB pathway. Int Immunopharmacol 2021;101:108339. [PMID: 34758440 DOI: 10.1016/j.intimp.2021.108339] [Reference Citation Analysis]
10 Mei Q, Liu Z, Zuo H, Yang Z, Qu J. Idiopathic Pulmonary Fibrosis: An Update on Pathogenesis. Front Pharmacol 2022;12:797292. [DOI: 10.3389/fphar.2021.797292] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
11 Bosch-Barrera J, Verdura S, Ruffinelli JC, Carcereny E, Sais E, Cuyàs E, Palmero R, Lopez-Bonet E, Hernández-Martínez A, Oliveras G, Buxó M, Izquierdo A, Morán T, Nadal E, Menendez JA. Silibinin Suppresses Tumor Cell-Intrinsic Resistance to Nintedanib and Enhances Its Clinical Activity in Lung Cancer. Cancers (Basel) 2021;13:4168. [PMID: 34439322 DOI: 10.3390/cancers13164168] [Reference Citation Analysis]
12 Qin H, Tang Y, Mao Y, Zhou X, Xu T, Liu W, Su X. C-MYC induces idiopathic pulmonary fibrosis via modulation of miR-9-5p-mediated TBPL1. Cell Signal 2022;:110274. [PMID: 35122989 DOI: 10.1016/j.cellsig.2022.110274] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Dong Y, Tang BX, Wang Q, Zhou LW, Li C, Zhang X, Sun DD, Sun X, Zhang XM, Xiong B, Li J, Shi H, Chen DQ, Zang Y. Discovery of a novel DDRs kinase inhibitor XBLJ-13 for the treatment of idiopathic pulmonary fibrosis. Acta Pharmacol Sin 2021. [PMID: 34819618 DOI: 10.1038/s41401-021-00808-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Bai X, Zhao G, Chen Q, Li Z, Gao M, Ho W, Xu X, Zhang XQ. Inhaled siRNA nanoparticles targeting IL11 inhibit lung fibrosis and improve pulmonary function post-bleomycin challenge. Sci Adv 2022;8:eabn7162. [PMID: 35731866 DOI: 10.1126/sciadv.abn7162] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Brinsi C, Abidi A, Hosni K, Tounsi H, Sebai H. Protective Effect of Eucalyptus globulus Extracts Against Bleomycin-Induced Pulmonary Fibrosis in Rats. J Med Food 2022;25:741-50. [PMID: 35834630 DOI: 10.1089/jmf.2021.0152] [Reference Citation Analysis]
16 Zang C, Zheng Y, Wang Y, Li L. The effects and safety of pirfenidone in the treatment of idiopathic pulmonary fibrosis: a meta-analysis and systematic review. Eur J Med Res 2021;26:129. [PMID: 34717762 DOI: 10.1186/s40001-021-00601-y] [Reference Citation Analysis]
17 Ding L, Li Y, Yang Y, Song S, Qi H, Wang J, Wang Z, Zhao J, Zhang W, Zhao L, Zhao D, Li X, Wang Z. Wenfei Buqi Tongluo Formula Against Bleomycin-Induced Pulmonary Fibrosis by Inhibiting TGF-β/Smad3 Pathway. Front Pharmacol 2021;12:762998. [PMID: 35126110 DOI: 10.3389/fphar.2021.762998] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Lu P, Li J, Liu C, Yang J, Peng H, Xue Z, Liu Z. Salvianolic acid B dry powder inhaler for the treatment of idiopathic pulmonary fibrosis. Asian Journal of Pharmaceutical Sciences 2022. [DOI: 10.1016/j.ajps.2022.04.004] [Reference Citation Analysis]
19 Luo X, Deng Q, Xue Y, Zhang T, Wu Z, Peng H, Xuan L, Pan G. Anti-Fibrosis Effects of Magnesium Lithospermate B in Experimental Pulmonary Fibrosis: By Inhibiting TGF-βRI/Smad Signaling. Molecules 2021;26:1715. [PMID: 33808650 DOI: 10.3390/molecules26061715] [Reference Citation Analysis]
20 Bos S, De Sadeleer LJ, Vanstapel A, Beeckmans H, Sacreas A, Yserbyt J, Wuyts WA, Vos R. Antifibrotic drugs in lung transplantation and chronic lung allograft dysfunction: a review. Eur Respir Rev 2021;30:210050. [PMID: 34415849 DOI: 10.1183/16000617.0050-2021] [Reference Citation Analysis]
21 Lina IA, Tsai HW, Berges AJ, Ospino RA, Davis RJ, Motz KM, Collins S, Ghosh B, Sidhaye V, Gelbard A, Hillel AT. Phenotypic Epithelial Changes in Laryngotracheal Stenosis. Laryngoscope 2022. [PMID: 35141889 DOI: 10.1002/lary.30040] [Reference Citation Analysis]
22 Zhang A, Zou Y, Xu Q, Tian S, Wang J, Li Y, Dong R, Zhang L, Jiang J, Wang L, Tao K, Meng Z, Liu Y. Investigation of the Pharmacological Effect and Mechanism of Jinbei Oral Liquid in the Treatment of Idiopathic Pulmonary Fibrosis Using Network Pharmacology and Experimental Validation. Front Pharmacol 2022;13:919388. [DOI: 10.3389/fphar.2022.919388] [Reference Citation Analysis]
23 Chang CJ, Lin CF, Chen BC, Lin PY, Chen CL. SHP2: The protein tyrosine phosphatase involved in chronic pulmonary inflammation and fibrosis. IUBMB Life 2021. [PMID: 34590785 DOI: 10.1002/iub.2559] [Reference Citation Analysis]